TY  - JOUR
AU  - Doyle, JS
AU  - Aspinall, E
AU  - Liew, D
AU  - Thompson, AJ
AU  - Hellard, ME
Y2  - 2014/05/22
Y2  - 2012/08/07
Y2  - 2012/08/07
Y2  - 2012/08/07
Y2  - 2012/08/07
Y2  - 2012/08/07
Y2  - 2012/08/07
Y2  - 2012/08/07
Y1  - 2013/04/01
SN  - 0306-5251
UR  - http://hdl.handle.net/11343/33201
AB  - Newly licensed direct acting antivirals for hepatitis C virus HCV are able to cure up to 75% of patients chronically infected with genotype-1 infection, which is the predominant HCV strain in Europe and North America. Emerging antiviral therapies promise further increases in virological response, as well as improved tolerability, reduced duration of therapy, and will potentially eliminate the need for interferon use. This review highlights the main therapeutic agents used in current standard of care, including telaprevir and boceprevir. It goes on to evaluate the mechanisms of emerging drugs, their stage of development and response rates seen in research to date. Finally, it projects into the not too distant future to consider treatment strategies involving combinations of agents and interferon-free therapies, and in which patients they might prove most successful.
N1  - application/pdf
LA  - English
PB  - WILEY
KW  - Infectious Diseases; Clinical Pharmacology and Therapeutics; Preventive Medicine
T1  - Current and emerging antiviral treatments for hepatitis C infection
DO  - 10.1111/j.1365-2125.2012.04419.x
IS  - British Journal of Clinical Pharmacology
VL  - 75
IS  - 4
SP  - 931-943
L1  - /bitstream/handle/11343/33201/298343_17345.pdf?sequence=1&isAllowed=n
ER  -